@ocuphire

We are a late-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies in refractive and retina disorders. $OCUP

 Farmington Hills, MI
ocuphire.com/
Joined February 2020
  • Tweets104
  • Following78
  • Followers163
13Media
Oral APX3330 outperformed placebo in slowing progression of #diabeticretinopathy in the phase 2 ZETA-1 trial, according to results presented by @ocuphire at the virtual Angiogenesis, Exudation and Degeneration 2024 conference. @Healio_OSN Read more! 👇 bit.ly/4bv6D6u
1
3
428
It’s #InternationalWomensDay everyday at Ocuphire. Cheers to a female led company! linkedin.com/posts/ocuphire-…
1
821
🙏Fortunate to present the results from the ZETA-1 study by Ocuphire on reducing the progression of diabetic retinopathy👁️with a first in class oral 💊agent. Promising results to help our patients see better. – at Miami, FL
3
3
1
39
4,808
linkedin.com/posts/ocuphire-…
466
Thank you @drrishisingh for presenting at #MaculaSociety2023 #diabeticretinopathy
Dr. Rishi P. Singh MD@drrishisingh18 Feb 2023
🙏Fortunate to present the results from the ZETA-1 study by Ocuphire on reducing the progression of diabetic retinopathy👁️with a first in class oral 💊agent. Promising results to help our patients see better.
1
6
1,003
Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings bit.ly/3xsskBl
3
346
Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye... bit.ly/3YImMya
1
1
2
293
Ocuphire Pharma retweeted
BioWorld
@BioWorld27 Jan 2023
After phase II miss, @ocuphire to seek a visual from @US_FDA on next steps in DR bioworld.com/articles/693675… #biotech #pharma
1
1
595
Ocuphire Pharma retweeted
Eyewire+@eyewireplus28 Jan 2023
.@ocuphire announced topline efficacy and safety results from its ZETA-1 phase 2 trial evaluating oral APX3330 for the treatment of #diabeticretinopathy (DR). bit.ly/3DnvlGj

Ocuphire Announces Phase 2 Topline Results of Oral Drug Candidate for Treatment of Diabetic...

Ocuphire Pharma announced topline efficacy and safety results from its ZETA-1 phase 2 trial evaluating oral APX3330 for the treatment of diabetic reti

eyewire.news
2
4
567
First patient enrolled in Ocuphire Phase 3 pivotal trial of Nyxol for presbyopia More: ow.ly/JPJG50MqpGw #Optometry #Presbyopia @ocuphire
1
2
480
Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for... bit.ly/3DbbFoX
5
2
304
Thank you, @OptometryTimes, for the opportunity to share our corporate highlights at the @aaopt meeting in Sunny San Diego! #Presbyopia #reversalofMydriasis #NightVisionDisturbances #diabeticnephropathy @Bindumanne
Optometry Times@OptometryTimes1 Jan 2023
Pipeline update from @ocuphire More: ow.ly/SW8150M9Vfa #Optomery #Pipeline
2
511
First patient enrolled in Ocuphire Phase 3 pivotal trial of Nyxol for presbyopia More: ow.ly/LsOU50Mlrzy #Optometry #Presbyopia #ClinicalTrial #Clinical @ocuphire
1
2
666
Join Mina Sooch, CEO, Charlie Hoffmann, VP, Corporate Development and Operations, and the management team at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. #jpm2023 $OCUP #jpm23 Reach out to Investor Relations at [email protected] to connect.
1
4
1,212
Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia bit.ly/3ZnV7DW
91
ICYMI: @ocuphire submits new drug application for eye drops for reversal of mydriasis More: ow.ly/O2oO50LXrcb #Optometry #Pipeline #Pediatrics
2
5
Ocuphire Pharma retweeted
Eyewire+@eyewireplus6 Dec 2022
.@ocuphire announces the submission of a NDA to the FDA for Phentolamine Ophthalmic Solution 0.75% (Nyxol) for the reversal of pharmacologically-induced #mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents, or a combination thereof. bit.ly/3HcMh5h

Ocuphire Pharma Submits New Drug Application to FDA for Nyxol Eye Drops for Reversal of Mydriasis -...

Ocuphire Pharma announced the submission of a new drug application (NDA) to the FDA for Phentolamine Ophthalmic Solution 0.75% (Nyxol) for t

eyewire.news
2
4
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis bit.ly/3F4JHeL
1
1
1
Ocuphire to Present at Five Upcoming Investor/Industry Conferences bit.ly/3tPDXAC
1
1
Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances. For more information, visit ocuphire.com/ #ophthalmology #optometry
1
2
1
6
Load more